Series II demonstrates how Agilent translates customer input and experience from development of the Agilent 5100 automated lab-on-a-chip platform assays into products that deliver better value
Agilent Technologies has introduced the Series II family of assay kits for the Agilent 2100 bioanalyser platform.
The Series II kits offer improvements in all specifications, including sensitivity, sizing range, robustness and sample matrix tolerance for RNA, DNA and protein.
"We've been developing lab-on-a-chip based assays since 1999, and have listened carefully to the needs of thousands of users," said Tobias Preckel, product marketing manager for Agilent's 2100 bioanalyser assays.
"Series II demonstrates how Agilent translates customer input and experience from development of the Agilent 5100 automated lab-on-a-chip platform assays into products that deliver better value".
In addition to improved specifications, the new kits offer an extended shelf life of a minimum of four months, which is expected to grow with further testing.
There is no price increase over existing 2100 lab-on-a-chip assay kits, and users will no longer need to purchase separate RNA ladders for the RNA assay.
The existing kits will be phased out in June 2006.
The new assay kits are reverse-compatible with all Agilent 2100 bioanalyser instruments.
A free software upgrade is required to run the new assays.
The improved Series II protein assays facilitate the replacement of time- and labour-intensive SDS-Page and capillary gel electrophoresis (CGE) measurements in research and regulated laboratories, with much faster microfluidic analyses.
While the new Protein 230 kit features an increased sizing range, higher sensitivity and salt tolerance, the new Protein 80 kit provides optimal performance for the analysis of proteins from 5 to 80kDa, which is ideal for analysing reduced antibodies.
